Rectal amputation sparing by haemostatic therapy with recombinant factor VIIa in a patient with cytomegalovirus–related colitis

• References

• 1 Goodgame RW. Gastrointestinal Cytomegalovirus disease. Ann Intern Med 1993; 119: 924-35.
• 2 Wong NA, Bathgate AJ, Bellamy CO. Colorectal disease in liver allograft recipients -a clinicopathological study with follow-up. Eur J Gastroenterol Hepatol 2002; 14: 231-6.
• 3 Matthes T, Kaiser L, Weber D. et al. Cytomegalovirus colitis - a severe complication after standard chemotherapy. Acta Oncol 2002; 41: 704-6.
• 4 Kozuka T, Takenaka K, Shinagawa K. et al. Cytomegalovirus enteritis after autologous peripheral blood stem cell transplantation. Ann Hematol 2001; 80: 617-9.
• 5 Cheung ANY, Ng IOL. Cytomegalovirus infection of the gastrointestinal tract in non-AIDS patients. Am J Gastroenterol 1993; 88: 1882-6.
• 6 Bini EJ, Weinshel EH, Falkenstein DB. Risk factors for recurrent bleeding and mortality in human immunodeficiency virus-infected patients with acute lower GI hemorrhage. Gastrointest Endosc 1999; 49: 748-53.
• 7 Nakamura T, Nakamura R, Maruyama K. et al. Refractory ulcerative colitis complicated by a Cytomegalovirus infection requiring surgery: report of a case. Surg Today 2004; 34: 58-71.
• 8 Han KJ, Jung IS, Kim CK. et al. A case of CMV disease of the jejunum in a patient with non-Hodgkin’s lymphoma. Korean J Int Med 1998; 13: 143-6.
• 9 Page MJ, Dreese JC, Portitz LS. et al. Cytomegalovirus enteritis: a highly lethal condition requiring early detection and intervention. Dis Colon Rectum 1998; 41: 619-23.
• 10 Abu-Hajir M, Hollowell J, Nagargoje G. Management of 2 patients with subdural hematoma and coagulopathy with recombinant human activated Factor VII (Novoseven, rVIIa). Blood 2001; 98: 79b.
• 11 Gerotziafas GT, Zervas C, Gavrieldis G. Effective haemostasis with rFVIIa treatment in two patients with severe thrombocytopaenia and life-threatening haemorrhage. AmJ Haematol 2002; 69: 219-22.
• 12 Poon MC, D’Oiron R. et al. Use of recombinant factor VIIa in patients with Glanzmann thromboasthenia. Semin Haematol 2001; 38: 21-5.
• 13 Almeida A, Khair K, Hann I. et al. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol 2003; 121: 477-81.
• 14 Stepinska J, Banaeszewski M, Konopka A. et al. Activated recombinant factor VIIa (rFVIIa) in bleeding management after therapy with IIb/IIIa-inhibitor Tirofiban. Thromb Haemost 2002; 87: 355-6.
• 15 Jeffers L, Chalasani N, Balart L. et al. Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. Gastroenterology 2002; 123: 118-26.
• 16 Grounds M. Recombinant factor VIIa and its use in severe bleeding in surgery and trauma: a review. Blood Reviews 2003; 17: S11-S21.
• 17 Boffard K D, Riou B, Warren B. et al. for the Novo-Seven Trauma Study Group. Recombinant Factor VIIa as Adjunctive Therapy for Bleeding Control in Severely Injured Trauma Patients: Two Parallel Randomized, Placebo-Controlled, Double-Blind Clinical Trials. J Trauma 2005; 59: 8-18.
• 18 Roberts HR, Monroe III DM, Hoffman M. Safety Profile of Recombinant Factor VIIa. Semin Hematol 2004; 41 (Suppl. 01) 101-8.
• 19 Ghorashian S, Beverly JH. Off license use of recombinant activated factor VII. Blood Reviews 2004; 18: 245-59.
• 20 Levi M, Peters M, Büller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: A systematic review. Crit Care Med 2005; 33: 883-90.
• 21 Veneri D, Franchini M. Successful treatment of intestinal hemorrhage in a Jehovah’s Witness patient. Am J Hematol 2005; 79: 344-5.
• 22 Martinowitz U, Michaelson M. on behalf of the Israeli Multidisciplinary rFVIIa Task Force. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost 2005; 03: 640-8.